Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13270430 | 0.82 | — | — | |
| SCHEMBL2743276 | 0.82 | — | — | |
| SCHEMBL8230672 | 0.82 | — | — | |
| SCHEMBL29252839 | 0.82 | NCF1 (0.39) | NCF1CYP1A2CYP2D6SLC6A2GNAI3 | |
| SCHEMBL8318641 | 0.81 | NCF1 (0.41) | NCF1CYP1A2CYP2D6SLC6A2ALDH1A1 | |
| Iodide SCHEMBL28581484 | 0.80 | — | — | |
| SCHEMBL20744284 | 0.79 | NCF1 (0.45) | NCF1CYP1A2CYP2D6SLC6A2ALDH1A1 | |
| SCHEMBL29271261 | 0.79 | INPP5A (0.42) | NCF1CYP1A2CYP2D6GNAI3GNAO1 | |
| SCHEMBL9699111 | 0.79 | INPP5A (0.42) | NCF1CYP1A2CYP2D6GNAI3GNAO1 | |
| SCHEMBL27391352 | 0.78 | NCF1 (0.52) | NCF1CYP1A2CYP2D6GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187460-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140364427-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| WO-2013090829-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364427-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | NCF1 2406/4885CYP1A2 434/4885CYP2D6 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.